Tourett's syndrome Tourett, tic, ramelteon, melatonin
Conditions
Interventions
Administration of 8 mg of melatonin daily at once before sleep, add to the previous treatment of participants.
Sponsors
SUGAWARA Masashiro
Akita University Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) 18-30 years of age. 2) Patient who fills the diagnostic criteria of "Tourette's disorder" according to the DSM-5. 3) Patient who can declare the one's written agreement to participate in the study.
Exclusion criteria
Exclusion criteria: 1) Having a history of other neurological and psychiatric disorders that can affect the motor and psychological function. 2) Having a distinct focal lesion on the brain MRI. 3) Patient who had change in the treatment within 4 weeks prior to the registration. 4) Patient who had been medicated ramelteon in the past. 5) Having liver dysfunction. 6) Having severe sleep apnea syndrome. 7) Taking an administration of fluvoxamine maleate.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Efficacy; Yale Global Tic Severity Scale (0 week, 2 week, 6 week, 8 week) | — |
Secondary
| Measure | Time frame |
|---|---|
| Y-BOCS, GTS-QOL, pattern of sleep, consentration of dopamin and serotonin in blood plasma, consentration of melatonin in saliva Safety; adversed events, vital signs (blood pressure, puls), laboratory data | — |
Contacts
Public ContactMasashiro SUGAWARA
Akita University Hospital
Outcome results
None listed